These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16809315)

  • 41. Functional role of type I and type II interferons in antiviral defense.
    Müller U; Steinhoff U; Reis LF; Hemmi S; Pavlovic J; Zinkernagel RM; Aguet M
    Science; 1994 Jun; 264(5167):1918-21. PubMed ID: 8009221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemically defined antiviral vaccines.
    Arnon R
    Annu Rev Microbiol; 1980; 34():593-618. PubMed ID: 6159823
    [No Abstract]   [Full Text] [Related]  

  • 43. The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons.
    Fragkoudis R; Breakwell L; McKimmie C; Boyd A; Barry G; Kohl A; Merits A; Fazakerley JK
    J Gen Virol; 2007 Dec; 88(Pt 12):3373-3384. PubMed ID: 18024907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model.
    Morris-Downes MM; Sheahan BJ; Fleeton MN; Liljeström P; Reid HW; Atkins GJ
    Vaccine; 2001 Jul; 19(28-29):3877-84. PubMed ID: 11427261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria.
    Mancuso G; Midiri A; Biondo C; Beninati C; Zummo S; Galbo R; Tomasello F; Gambuzza M; Macrì G; Ruggeri A; Leanderson T; Teti G
    J Immunol; 2007 Mar; 178(5):3126-33. PubMed ID: 17312160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alphavirus hybrid virion vaccines.
    Shafferman A; Lustig S; Inbar Y; Halevy M; Schneider P; Bino T; Leitner M; Grosfeld H; Velan B; Schödel F; Cohen S
    Adv Exp Med Biol; 1996; 397():41-7. PubMed ID: 8718580
    [No Abstract]   [Full Text] [Related]  

  • 47. Antiviral activity of autocrine interferon-beta requires the presence of a functional interferon type I receptor.
    Rousseau V; Cremer I; Lauret E; Rivière I; Aguet M; De Maeyer E
    J Interferon Cytokine Res; 1995 Sep; 15(9):785-9. PubMed ID: 8536106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis.
    Boere WA; Benaissa-Trouw BJ; Harmsen M; Kraaijeveld CA; Snippe H
    J Gen Virol; 1983 Jun; 64 (Pt 6)():1405-8. PubMed ID: 6854274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.
    Marchese AM; Chiale C; Moshkani S; Robek MD
    J Interferon Cytokine Res; 2020 Feb; 40(2):92-105. PubMed ID: 31633442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alphavirus-Based Vaccines.
    Lundstrom K
    Methods Mol Biol; 2017; 1581():225-242. PubMed ID: 28374252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cross-reactive, cell-associated antigen on L929 cells infected with temperature-sensitive mutants of sindbis virus.
    Wolcott JA; Gates DW; Wust CJ; Brown A
    Infect Immun; 1982 May; 36(2):704-9. PubMed ID: 6177636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.
    Kim JJ; Yang JS; VanCott TC; Lee DJ; Manson KH; Wyand MS; Boyer JD; Ugen KE; Weiner DB
    J Virol; 2000 Apr; 74(7):3427-9. PubMed ID: 10708463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune defence in mice lacking type I and/or type II interferon receptors.
    van den Broek MF; Müller U; Huang S; Zinkernagel RM; Aguet M
    Immunol Rev; 1995 Dec; 148():5-18. PubMed ID: 8825279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection.
    Alsharifi M; Lobigs M; Regner M; Lee E; Koskinen A; Müllbacher A
    J Immunol; 2005 Oct; 175(7):4635-40. PubMed ID: 16177109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early type I IFN blockade improves the efficacy of viral vaccines.
    Palacio N; Dangi T; Chung YR; Wang Y; Loredo-Varela JL; Zhang Z; Penaloza-MacMaster P
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32820330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-12 as an adjuvant for induction of protective antibody responses.
    Metzger DW
    Cytokine; 2010; 52(1-2):102-7. PubMed ID: 20650650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice.
    Smee DF; Alaghamandan HA; Jin A; Sharma BS; Jolley WB
    Antiviral Res; 1990 Feb; 13(2):91-102. PubMed ID: 1693058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Control of Sindbis virus infection by antibody in interferon-deficient mice.
    Byrnes AP; Durbin JE; Griffin DE
    J Virol; 2000 Apr; 74(8):3905-8. PubMed ID: 10729167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forest virus infection.
    Morahan PS; Pinto A; Stewart D; Murasko DM; Brinton MA
    Antiviral Res; 1991; 15(3):241-54. PubMed ID: 1653557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.
    Pepini T; Pulichino AM; Carsillo T; Carlson AL; Sari-Sarraf F; Ramsauer K; Debasitis JC; Maruggi G; Otten GR; Geall AJ; Yu D; Ulmer JB; Iavarone C
    J Immunol; 2017 May; 198(10):4012-4024. PubMed ID: 28416600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.